Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments 
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Apple Turns 50: From Garage Startup to AI Crossroads 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic 
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
Dublin, Dec. 23, 2016 -- Research and Markets has announced the addition of the "Fabry Disease Drugs Price Analysis and Strategies - 2016" report to their offering.
Fabry Disease Drugs Price Analysis and Strategies 2016, provides drug pricing data and benchmarks in the global Fabry Disease market.
The research answers the following questions:
- What are the key drugs marketed for Fabry Disease and their clinical attributes? How are they positioned in the Global Fabry Disease market?
- What are the unit prices and annual treatment cost for Fabry Disease therapies in different countries? What are the drug pricing trends and how are they expected to change in the future? How are the drug pricing and reimbursement landscape different by countries?
- What are the unmet needs in the global Fabry Disease drugs market? What would be the ideal pricing strategy for a new pipeline therapy for Fabry Disease?
Research Scope:
- Treatment Options - Identify key drugs marketed and prescribed for Fabry Disease including trade name, molecule name, and company
- Drugs Attributes - Find out the safety, efficacy, and risk benefit for key drugs marketed for Fabry Disease
- Market Positioning - Identify how drugs are clinically and commercially positioned in the global Fabry Disease market
- Fabry Disease Drugs Price Analysis - Find out the annual therapy cost and unit price for key drugs marketed
- Find out how the price advanced from 2012 and forecast to 2021
- Pricing & Reimbursement Landscape - Find out the pricing and reimbursement landscape
- Fabry Disease New Drug Pricing - Identify the effective pricing strategy for a new drug launch
Key Topics Covered:
1. Treatment Options
2. Drugs Clinical Attributes
3. Drugs Market Positioning
4. Drugs Price Analysis
5. Drugs Price Benchmarks
6. Drug Pricing & Reimbursement Landscape
7. Drugs Price Forecast
8. Market Unmet Needs
9. New Drug Pricing
For more information about this report visit http://www.researchandmarkets.com/research/djpxqp/fabry_disease
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Endocrine and Metabolic Disorder Drugs
